(Q39456483)

12 September 2017

0 references

Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis (English)

1 reference

12 September 2017

0 references

1 reference

6

Gregory Y H Lip

1 reference

Lipid and Blood Pressure Meta-analysis Collaboration Group

12 September 2017

13

object named as

Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group

1 reference

12 September 2017

12

Maciej Banach

1 reference

12 September 2017

Dimitri P Mikhailidis

2

object named as

Dimitri P Mikhailidis

1 reference

12 September 2017

Alberico L Catapano

8

0 references

Paul Muntner

7

object named as

Paul Muntner

1 reference

12 September 2017

9

Michael J Pencina

1 reference

12 September 2017

11

Jacek Rysz

1 reference

12 September 2017

10

Robert S Rosenson

1 reference

12 September 2017

1

Kamal Awad

1 reference

12 September 2017

3

Peter P Toth

1 reference

12 September 2017

Steven R Jones

4

1 reference

12 September 2017

Patrick Moriarty

5

1 reference

12 September 2017

language of work or name

1 reference

24 July 2017

1 reference

Cardiovascular Drugs and Therapy

12 September 2017

published in

1 reference

Current and future treatment of hyperlipidemia: the role of statins

12 September 2017

volume

31

0 references

issue

4

0 references

page(s)

419-431

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Statins for the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study o

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

The influence of statin characteristics on their safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

A general assessment of the safety of HMG CoA reductase inhibitors (statins).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

How do we improve patient compliance and adherence to long-term statin therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Discussion around statin discontinuation in older adults and patients with wasting diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Lipids, blood pressure and kidney update 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Expert opinion: the therapeutic challenges faced by statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Narrative review: statin-related myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Managing the underestimated risk of statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Interpretation of the evidence for the efficacy and safety of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Efficacy of alternate day versus daily dosing of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Efficacy of alternate-day dosing versus daily dosing of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Estimating the mean and variance from the median, range, and the size of a sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Standard deviations and standard errors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Maintenance of low-density lipoprotein goal with step-down pravastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Efficacy of alternate-day versus everyday dosing of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Non-every day statin administration--a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Alternate-day statin therapy for the treatment of hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Statins and the risk of new-onset diabetes: a review of recent evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-017-6743-0

10.1007/S10557-017-6743-0

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference